What happens when the world of GLP-1s collides with the operating room? Today, we’re diving into the new era of obesity care.

Hosts
· Matthew Martin, trauma and bariatric surgeon at the University of Southern California/Los Angeles General Medical Center (Los Angeles, California) @docmartin2
· Adrian Dan, bariatric and MIS surgeon, program director for the advanced MIS bariatric and foregut fellowship at Summa Health System (Akron, Ohio) @DrAdrianDan
· Crystal Johnson Mann, bariatric and foregut surgeon at the University of Florida (Gainesville, Florida) @crys_noelle_
· Katherine Cironi, general surgery resident at the University of Southern California/Los Angeles General Medical Center (Los Angeles, California) @cironimacaroni

Learning objectives
1. Understand the evolving role of OMMs in bariatric surgical practice
· Recognize how widespread GLP-1 and dual-incretin therapies have reshaped patient presentations, expectations, and referral patterns.
· Appreciate current evidence comparing surgery to GLP-1 therapy, including the JAMA Surgery study out of Allegheny Health (2025), noting:
o Superior weight loss with bariatric surgery (~28% TBWL vs ~10% with GLP-1s)
o Higher health-care utilization and cost in GLP-1–treated patients.
· Frame OMMs not as alternatives but as complementary tools within a chronic disease model when treating obesity.
2. Review pharmacologic classes and their expected efficacy
· Surgeons should be able to articulate the mechanisms, efficacy, and limitations of:
o GLP-1 receptor agonists – incretin-based satiety; 5–12% TBWL.
o Dual GIP/GLP-1 agonists – most potent agents; 15–22% TBWL.
o Sympathomimetics – norepinephrine-driven appetite suppression; 3–7% TBWL.
o Combination agents (bupropion-naltrexone, phentermine-topiramate) – 5–12% TBWL depending on regimen.
o Emerging therapies – retatrutide, maritide, oral GLP-1s, with promising TBWL in phase 2 trials
3. Apply OMMs strategically in the preoperative phase
· Integrate OMMs without compromising surgical eligibility—OMM-related weight loss does not negate the indication for surgery.
· Counsel patients that medication response does not equal disease resolution; surgery remains the most durable intervention.
· Manage delayed gastric emptying and aspiration risk:
o Pause weekly GLP-1 or dual agonists for ≥1 week pre-op (longer if symptomatic).
o Collaborate closely with the anesthesia/OR teams
· Screen for nutritional depletion before surgery, especially protein deficits exacerbated by appetite suppression.
· Navigate insurance barriers that may paradoxically approve surgery but deny medication continuation.
4. Implement postoperative OMMs safely and effectively
· Establish criteria for OMM introduction:
o Typical initiation at 6–12 months, once the diet stabilizes and the physiologic curve flattens.
o Earlier initiation (4–6 weeks) may be appropriate in pediatric or select high-risk populations.
· Recognize altered pharmacokinetics after sleeve and bypass:
o Injectables may be preferred due to altered absorption of oral agents.
· Prevent postoperative nutritional compromise:
o Monitor protein intake, hydration, and micronutrient status (including iron, B12, and fat-soluble vitamins).
o Titrate doses slowly to minimize nausea/vomiting that can precipitate malnutrition.
· Frame OMM use as a tool for disease persistence (plateau/regain), not as a marker of failure.
5. Identify systems-level barriers and the implementation of coordinated care
· Understand insurance inconsistencies—coverage for surgery is often not paired with coverage for long-term medical therapy.
· Clearly document disease persistence and medical necessity when appealing denials.
· Avoid fragmented care: establish shared-care pathways between bariatric surgery, obesity medicine, and primary care.
· Use patient-centered language emphasizing complementary therapy, not hierarchy or competition between surgery and medications.
6. Counsel patients ethically and accurately within a chronic disease model
· Set expectations: sustained success requires surgery + medication + behavioral change.
· Educate patients that postoperative OMM use does not imply surgical failure.
· Normalize long-term multimodal management of obesity, analogous to diabetes or hypertension models.

*Sponsor Disclaimer: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only